LIFECORE BIOMEDICAL, INC. Proceeds from Long-Term Debt Issued
LIFECORE BIOMEDICAL, INC. (LFCR) reported Proceeds from Long-Term Debt Issued of $0 for the 9-month period ending 2024-02-25, per its 10-Q filed 2024-08-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2024-08-09
- LIFECORE BIOMEDICAL, INC. proceeds from issuance of long-term debt for the quarter ending 2023-05-28 was $146.63M, a 633.16% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. proceeds from issuance of long-term debt for the quarter ending 2022-05-29 was $20.00M, a 0.00% change year-over-year.
- LIFECORE BIOMEDICAL, INC. proceeds from issuance of long-term debt for the quarter ending 2021-05-30 was $20.00M.
- LIFECORE BIOMEDICAL, INC. proceeds from issuance of long-term debt for the quarter ending 2021-02-28 was $150.00M.
- LIFECORE BIOMEDICAL, INC. proceeds from issuance of long-term debt for fiscal 2023 was $150.00M, a 650.00% increase from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. proceeds from issuance of long-term debt for fiscal 2022 was $20.00M, a 88.24% decline from fiscal 2021.
- LIFECORE BIOMEDICAL, INC. proceeds from issuance of long-term debt for fiscal 2021 was $170.00M, a 518.18% increase from fiscal 2020.
- LIFECORE BIOMEDICAL, INC. proceeds from issuance of long-term debt for fiscal 2020 was $27.50M, a 54.17% decline from fiscal 2019.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2024-02-25 | $0.00 10-Q · filed 2024-08-09 | |||
| 2023-05-28 | $146.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $150.00M 10-K · filed 2024-03-20 | ||
| 2023-02-26 | $3.37M 10-Q · filed 2024-08-09 | |||
| 2022-05-29 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $20.00M 10-K · filed 2024-03-20 | ||
| 2022-02-27 | $0.00 10-Q · filed 2023-06-02 | |||
| 2021-05-30 | $20.00M derived: 10-K 12 month − 10-K 9 month · filed 2024-03-20 | $170.00M derived: sum of 2 quarters · filed 2024-03-20 | $170.00M 10-K · filed 2024-03-20 | |
| 2021-02-28 | $150.00M derived: 10-K 9 month − 10-Q 6 month · filed 2024-03-20 | $150.00M 10-K · filed 2024-03-20 | ||
| 2020-11-29 | $0.00 10-Q · filed 2021-01-07 | |||
| 2020-05-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $27.50M 10-K/A · filed 2023-03-16 | |
| 2020-02-23 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-04-08 | $27.50M 10-Q · filed 2021-04-08 | ||
| 2019-11-24 | $27.50M 10-Q · filed 2021-01-07 | |||
| 2019-05-26 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-29 | $60.00M derived: sum of 2 quarters · filed 2021-07-29 | $60.00M 10-K · filed 2021-07-29 | |
| 2019-02-24 | $60.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-04-03 | $60.00M 10-Q · filed 2020-04-03 | ||
| 2018-11-25 | $0.00 10-Q · filed 2020-01-02 | |||
| 2018-05-27 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-14 | $0.00 10-K · filed 2020-08-14 | ||
| 2018-02-25 | $0.00 10-Q · filed 2019-04-04 | |||
| 2017-05-28 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-08-01 | $0.00 derived: sum of 2 quarters · filed 2019-08-01 | $50.00M 10-K · filed 2019-08-01 | |
| 2017-02-26 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-04-05 | $50.00M 10-Q · filed 2018-04-05 | ||
| 2016-11-27 | $50.00M 10-Q · filed 2018-01-05 | |||
| 2016-05-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-09 | $16.78M derived: sum of 2 quarters · filed 2018-08-09 | $26.75M 10-K · filed 2018-08-09 | |
| 2016-02-28 | $16.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-04-07 | $26.75M 10-Q · filed 2017-04-07 | ||
| 2015-11-29 | $9.97M 10-Q · filed 2017-01-05 | |||
| 2015-05-31 | $3.82M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-03-15 | $3.82M derived: sum of 2 quarters · filed 2018-03-15 | $7.94M derived: sum of 3 quarters · filed 2018-03-15 | $15.01M 10-K/A · filed 2018-03-15 |
| 2015-03-01 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-03-30 | $4.12M derived: sum of 2 quarters · filed 2016-03-30 | $11.19M 10-Q · filed 2016-03-30 | |
| 2014-11-30 | $4.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-01-07 | $11.19M 10-Q · filed 2016-01-07 | ||
| 2014-08-31 | $7.07M 10-Q · filed 2015-10-01 | |||
| 2012-05-27 | $31.82M 10-K · filed 2014-08-01 | |||
| 2010-05-30 | $20.00M 10-K · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |